scholarly journals Static Image Analysis as New Approach for the Characterization of Tumor Cell Lysate Used in Dendritic Cell Vaccine Preparation

2015 ◽  
Vol 42 (2) ◽  
pp. 122-128 ◽  
Author(s):  
Isabelle Müller ◽  
Dorothee Hartmann ◽  
Joachim Oertel ◽  
Cornelia M. Keck ◽  
Hermann Eichler
Keyword(s):  
Image Analysis ◽  
Dendritic Cell ◽  
Tumor Cell ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
New Approach ◽  
Vaccine Preparation ◽  
Cell Lysate ◽  
Tumor Cell Lysate

scholarly journals 423. The Combination of p53 Dendritic Cell Vaccine and Ad-p53 Gene Therapy Against p53 Overexpressing and p53 Deleted Tumor Cell Lines

2015 ◽  
Vol 23 ◽  
pp. S167
Author(s):  
Hiroki Saito ◽  
Koichi Kitagawa ◽  
Risa Yamasaki ◽  
Nami Katai ◽  
Naoya Morishita ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Dendritic Cell ◽  
Tumor Cell ◽  
Cell Lines ◽  
P53 Gene ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Tumor Cell Lines

scholarly journals Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 25 ◽  
Author(s):  
Caroline Boudousquié ◽  
Valérie Boand ◽  
Emilie Lingre ◽  
Laeticia Dutoit ◽  
Klara Balint ◽  
...  
Keyword(s):  
T Cell ◽  
Dendritic Cell ◽  
Tumor Cell ◽  
Manufacturing Process ◽  
Tumor Lysate ◽  
Cell Lysate ◽  
Cell Factories ◽  
Dc Vaccine ◽  
Dc Vaccines ◽  
Tumor Cell Lysate

With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here, we describe the development and optimization of a Good Manufacturing Practice (GMP)-compliant manufacturing process based on tumor lysate as a tumor antigen source for the production of an oxidized tumor cell lysate loaded DC (OC-DC) vaccine. The manufacturing process required one day for lysate preparation and six days for OC-DC vaccine production. Tumor lysate production was standardized based on an optimal tumor digestion protocol and the immunogenicity was improved through oxidation using hypochloric acid prior to freeze-thaw cycles resulting in the oxidized tumor cell lysate (OC-L). Next, monocytes were selected using the CliniMACS prodigy closed system and were placed in culture in cell factories in the presence of IL-4 and GM-CSF. Immature DCs were loaded with OC-L and matured using MPLA-IFNγ. After assessing the functionality of the OC-DC cells (IL12p70 secretion and COSTIM assay), the OC-DC vaccine was cryopreserved in multiple doses for single use. Finally, the stability of the formulated doses was tested and validated. We believe this GMP-compliant DC vaccine manufacturing process will facilitate access of patients to personalized DC vaccines, and allow for multi-center clinical trials.

Sign in / Sign up

Export Citation Format

Share Document